Business · 1 sources covering this

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·1h ago
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/59b41ed7798fd85f7b80bf1b4edfa9fd73024d24"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis"></iframe>

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

How 1 sources are covering this

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

More from Business

September data shows housing market in a deep freeze

LightStream stops accepting loan applications. Try these 6 lenders instead

Data center stocks slide as Korea IPO plunges 30%, pressuring tech sentiment

General Motors beats Wall Street's Q3 earnings expectations, narrows full-year guidance

Reader

Trust & legal

Across the network